secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-07-16T20:07:03+00:00
Accession:  0001178913-26-003510
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio shareholders approve 2.5x increase in authorized shares to 350M and 2.5M share increase in equity plan
--------------------------------------------------------------------------------

- Authorized ordinary shares increased from 140,010,000 to 350,000,000 effective July 14, 2026.
- 2018 Equity Incentive Plan amended to add 2,500,000 ordinary shares for issuance.
- All director nominees elected: Sean Ellis, Steven D. Rubin, Geno H. Germano (Class III, three-year terms).
- Shareholders approved non-executive director compensation, share-based grants, and advisory say-on-pay.
- Kesselman & Kesselman (PwC) ratified as independent auditor for FY 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/0001178913-26-003510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/zk2635691.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-003510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer